Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
32 studies found for:    "Li Fraumeni syndrome"
Show Display Options
Rank Status Study
21 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
22 Active, not recruiting To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Condition: Small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Biological: Drug: Ad.p53-DC vaccines;   Drug: All -trans Retinoic Acid (ATRA)
23 Recruiting p53 and Response to Preoperative Radiotherapy for T2 and T3
Condition: Rectal Cancer
Intervention: Radiation: preoperative short course radiation
24 Recruiting Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors
Condition: Carcinoma, Solid Tumor
Intervention: Drug: ALRN-6924
25 Active, not recruiting Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Cisplatin;   Biological: ALT-801
26 Completed
Has Results
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Condition: Progressive Metastatic Malignancies
Intervention: Biological: ALT-801
27 Recruiting Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Conditions: Familial Ovarian Cancer;   Familial Breast Cancer;   BRCA1-associate Malignancies;   BRCA2-associated Malignancies
Intervention:
28 Active, not recruiting A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Intervention: Biological: ALT-801
29 Recruiting A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Conditions: Transitional Cell Carcinoma of Bladder;   Urethra Cancer;   Ureter Cancer;   Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Biological: ALT-801
30 Recruiting A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Condition: Non-muscle Invasive Bladder Cancer
Interventions: Biological: ALT-801;   Drug: Gemcitabine
31 Withdrawn Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Condition: Acute Myelogenous Leukemia
Interventions: Drug: cenersen;   Drug: placebo;   Drug: idarubicin, cytarabine
32 Completed P53 in Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-32) Next Page   
Indicates status has not been verified in more than two years